Sisram Medical's Q3 2025 Progress Highlights Strong Market Growth

Author: Thomas Cooper Updated: 10-28-2025 08:28 AM

Sisram Medical Reports Impressive Performance in Q3 2025

Sisram Medical Ltd, a global leader in medical aesthetic solutions, recently reported a robust business update for the third quarter of 2025, showcasing solid revenue growth and strong momentum in its core product segments.

Outstanding Revenue Growth Driven by Strong Demand

For Q3 2025, Sisram Medical achieved remarkable revenue growth over the previous year, propelled by a significant increase in new orders. This growth was primarily attributed to heightened demand from crucial markets. Countries such as China, South Korea, and Thailand have exhibited substantial needs for Sisram's innovative offerings.

Continued Success in Energy-Based Devices

The Energy-Based Devices (EBD) segment has shown impressive growth, particularly with the Alma Harmony platform. This award-winning technology, introduced globally in March 2025, has seen a surge in new orders reflecting its popularity and market effectiveness. The Soprano family of laser devices has also performed exceptionally well, especially with a recent launch in a leading market that bolstered order volumes.

Injectables Segment Paves the Way for Future Growth

Additionally, Sisram's injectables business continues to be a major driver of growth. The recent approval of DAXXIFY by the regulatory authority in Mainland China marks a significant milestone for the company. As the first botulinum toxin type A product utilizing proprietary Peptide Exchange Technology, DAXXIFY is positioned to revolutionize the injectables market.

Strategic Market Expansion Initiatives

Sisram Medical is actively deepening its market presence through strategic initiatives. The establishment of a direct sales office has enabled Sisram to effectively localize its offerings, proving successful in generating injectable sales. Moreover, the recent launch of Universkin by Alma, the first AI-driven skincare product line, signifies Sisram's commitment to innovation and addressing evolving consumer needs.

CEO Insights on Business Performance

Mr. Lior Dayan, CEO of Sisram and Alma, expressed his enthusiasm regarding the third-quarter results. He emphasized the significance of the growth strategy that the company has been executing. The dual focus on EBD and injectables has positioned Sisram well for sustainable expansion and value creation in the aesthetic solutions market.

About Sisram Medical Ltd

Sisram Medical Ltd is a pioneer in the medical aesthetic industry, specializing in Energy-Based Devices and injectables with over 25 years of experience. The company operates in over 110 countries, providing innovative solutions that enhance safety, efficacy, and personalized care for aesthetic treatments.

Frequently Asked Questions

What were Sisram Medical's revenue growth rates in Q3 2025?

Sisram Medical saw double-digit revenue growth compared to the previous year, indicating strong demand across key markets.

How is Sisram Medical performing in its Energy-Based Devices segment?

The EBD segment, including products like Alma Harmony and Soprano devices, has maintained high growth rates, supported by substantial new orders.

What is the significance of DAXXIFY for Sisram Medical?

DAXXIFY's approval marks a significant expansion in Sisram's injectables portfolio, featuring innovative technology that enhances its product offerings in China.

Which markets are driving Sisram's growth?

Key markets driving growth include China, South Korea, and Thailand, where demand for aesthetic solutions continues to rise.

What future initiatives is Sisram planning?

Sisram aims to expand its market presence and enhance customer engagement through localized strategies and innovative product launches.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.